Extended Data Fig. 2: Assessment of vaccine-specific ASC and validation of vaccine specificities with blood ASC.
(a) Summary of the techniques and the experimental designs. From the cultures of blood ASC, the cells were collected and ELISpot-quantitated for validating vaccine specificities. (b) Representative ELISpot scanned images shown. Blood ASC from subjects at the peak (5-7 days post-vaccine) assayed for Flu-, Tet-, and S2P-specific IgG secretion. The numbers of input ASC that were incubated were ~894, ~1,124, and ~796 (total), and ~4,471, ~4,496, and ~2,388 (Flu-specific) for S#1, S#2, and S#3, respectively (far left); ~1 K, ~1 K, and ~1 K (total), and ~3 K, ~4 K, and ~4 K (Tet-specific) for S#4, S#5, and S#6, respectively (left); and ~712, ~1,415, and ~1,386 (total), and ~2,139, ~4,245, and ~5,544 (S2P-specific) for S#7, S#8, and S#9, respectively (right). (c) Each circle represents an individual vaccinee. Data were generated from 3, 3, 3, 8, 6, and 5 different vaccinated subjects for Flu, Tet, S2P (v1), S2P (v2), S2P (v3), and S2P (v4), respectively. S: subject; ~: counts provided by the sorters; K: 1,000; vac: vaccinated; Flu: influenza; Tet: tetanus; v: (SARS-CoV-2 mRNA) vaccine dose. All ASC assayed at day 1 in culture.
